Cent raises $15 million; preventive scanning still has to prove what happens after a finding

A mixed Series A, not $15 million of disclosed equity

Cent has raised $15 million through a combination of debt and equity, led by Blume Ventures and existing investor South Park Commons, according to October 27 reporting from YourStory and StartupTalky. Neither account discloses the split. The entire amount should not be described as new equity, and the supplied evidence does not establish repayment terms or a valuation.

The preventive-health company says the funding will support research and development and its AI, engineering and clinical teams. Those are intended uses of reported raised financing, not evidence that the planned expansion is complete. YourStory names Shashank ND, Arpit Garg and Anshul Khandelwal as the founders of Cent, established in 2025.

Separate the platform, the activity and the ambition

YourStory’s company-statement account describes hardware, AI-assisted radiology and diagnostics, and bioinformatics within a vertically integrated platform. That is the company’s description of what it is building. The funding reports do not independently establish the medical effectiveness of the resulting service.

Cent says it has completed 10,000 preventive whole-body scans across Bengaluru, Mumbai and Delhi since inception, according to YourStory. The same account reports its target of ten million scans by 2035. The first is a company-reported activity count; the second is a future ambition. StartupTalky questions the consistency of the scan-count definitions; the supplied accounts do not resolve that issue. Neither figure should be rewritten as a demonstrated patient benefit or an independently established growth forecast.

YourStory also reports Cent’s acquisition of Medsee, a radiology reporting workflow platform that drafts structured reports and highlights findings for qualified professional review. This is an assistance workflow, not evidence that an autonomous system replaces a radiologist. The financing announcement and that reported acquisition are related developments, but the new round does not itself validate the acquired product’s clinical performance.

The unanswered question is clinical follow-through

StartupTalky relays Cent’s claim that one in four members who felt well had a finding worth acting on and one in forty needed immediate medical attention. These are disclosed company claims, not independently confirmed diagnoses or comparative patient-outcome evidence. The reports do not establish the definitions and denominators needed to interpret those rates as disease incidence. A scan produces information; whether it benefits a person depends on professional assessment and appropriate follow-through.

That absence does not prove that the service is ineffective. It defines what this announcement can support: a reported mixed financing round, a company-described platform and company-attributed activity and target figures. It cannot support a recommendation that healthy people undergo this screening, or a claim that scan growth alone improves their health.

Cent’s financing advances its company-building programme. A future assessment of its preventive-health proposition would need clinical evidence about the complete service, not only the speed of a draft report or the number of scans. Founder experience, investment and activity can be relevant context without substituting for that evidence.